drugset / Trial / NCT07271251

A Research Study to See if Two Different Formulations of Oral Semaglutide Are Equally Safe and Effective in Reducing the Blood Sugar Level in Japanese People With Type 2 Diabetes

NCT07271251

Phase 3 Active not recruiting 264 enrolled Novo Nordisk A/S
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of the study is to find out if the new tablet formulation oral semaglutide D is equally safe and effective as the approved oral semaglutide for treating Japanese people with type 2 diabetes. Participants will receive either oral semaglutide D (the treatment being tested) or oral semaglutide (the comparator); which treatment a participant gets is decided by chance. Oral semaglutide is an approved tablet (a treatment used as a comparator), while oral semaglutide D is described as the new tablet formulation being tested in this study. The study will last approximately 27 weeks.

Timeline

Start
2025-12-01
Primary completion
2026-06-29
Completion
2026-08-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Semaglutide Peptide Oral